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Background
Genotypic algorithms used to predict the clinical efficacy
of lopinavir/ritonavir (LPV/r) have included a range of
mutation lists and efficacy end-points. HIV clinical trials
are normally powered to detect a difference between treat-
ment arms of 10–12% for the end-point of HIV-1 RNA
suppression <50 copies/mL. The TITAN trial (TMC114-
C214) evaluated LPV/r vs. darunavir/ritonavir in treat-
ment-experienced patients with HIV-1 RNA >1000 copies/
mL. Baseline genotypic resistance to darunavir was rare in
the TITAN trial.
Methods
Baseline genotype data were classified using seven geno-
typic resistance algorithms: IAS-USA LPV mutations (cut-
off = 6), Abbott 2007 (King) mutation list (cut-off = 3),
ANRS mutations (cut-off = 6), FDA mutations (cut-off =
3), Stanford, REGA and IAS-USA major PI mutations. Effi-
cacy in the TITAN trial (HIV-1 RNA <50 at week 48) was
correlated with the number of mutations from each list, to
show the "efficacy advantage cut-off level": the number of
mutations from each list associated with a difference in
efficacy between treatment arms of at least 12%. The line-
arity of the correlation between mutation count and effi-
cacy of LPV/r was analysed in TITAN, with sensitivity
analysis for the French LPV ATU, BMS-045 and RESIST tri-
als.
Summary of results
In TITAN, the concordance between baseline lopinavir
resistance, defined by the mutation scores, ranged from
79–95%. Multivariate analysis identified lower than pre-
viously reported genotypic cut-off levels where there was
at least 12% lower efficacy for LPV/r versus darunavir/
ritonavir. These "efficacy advantage cut-off levels" were:
IAS-USA LPV mutations, cut-off = 3; Abbott 2007, cut-off
= 2; ANRS LPV cut-off = 3; FDA LPV mutations, cut-off = 2
and major IAS-USA PI mutations, cut-off = 1, Stanford
algorithm, cut-off = low level LPV resistance; REGA algo-
rithm, cut-off = Intermediate level LPV resistance. There
were linear falls in HIV-1 RNA suppression rates with ris-
ing mutation counts in the TITAN, French LPV ATU, BMS-
045 and RESIST trials.
Conclusion
The analysis identified more sensitive cut-off levels for
several lopinavir genotypic algorithms, below those cur-
rently used, at which there is significant efficacy advantage
for treatment with darunavir/ritonavir versus lopinavir/
ritonavir in the TITAN trial. These new cut-off levels also
detect a higher percentage of patients with virological fail-
ure than previous cut-off levels.
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